Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.78 |
| ▸ | TEC | P42680 | 2/20 | 0.78 |
| ▸ | TXK | P42681 | 2/20 | 0.78 |
| ▸ | BMX | P51813 | 2/20 | 0.78 |
| ▸ | EGFR | P00533 | 1/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.78 |
| ▸ | KDR | P35968 | 1/20 | 0.78 |
| ▸ | BLK | P51451 | 1/20 | 0.78 |
| ▸ | JAK3 | P52333 | 1/20 | 0.78 |
| ▸ | ITK | Q08881 | 1/20 | 0.78 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.78 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.78 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acalabrutinib SCHEMBL14637370 | 0.87 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL30193365 | 0.87 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL29376537 | 0.87 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL17842601 | 0.87 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL31756796 | 0.87 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL14637368 | 0.87 | BTK (1.00) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL18423041 | 0.86 | BTK (0.97) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL18423036 | 0.86 | BTK (0.97) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL18422158 | 0.85 | BTK (0.96) | BTKTECTXKBMXEGFR | |
| Acalabrutinib SCHEMBL18422160 | 0.85 | BTK (0.96) | BTKTECTXKBMXEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160074409-A1 | Treatment of Skeletal-Related Disorders | ROTHBAUM WAYNE (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160074409-A1 | Treatment of Skeletal-Related Disorders | ROTHBAUM WAYNE (US) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074409-A1 | Treatment of Skeletal-Related Disorders | SOST, COL2A1, CYP27B1 | BTK 4374/4885TEC 4674/4885TXK 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.